Evidence map›Paper›PMID 34300311›Full record

ArticleJournal of clinical medicine2021

Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis.

João Oliveira, Joana Gameiro, João Bernardo, Filipe Marques, Cláudia Costa, Carolina Branco, Inês Duarte, José Fonseca, Carolina Carreiro, Sandra Braz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

João OliveiraDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0001-5097-9630
Joana GameiroDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0001-6143-461X
João BernardoDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.
Filipe MarquesDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.
Cláudia CostaDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0002-6468-1306
Carolina BrancoDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0002-3073-0253
Inês DuarteDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0003-0101-9961
José FonsecaDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0001-7675-216X
Carolina CarreiroDepartment of Internal Medicine, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.
Sandra BrazDepartment of Internal Medicine, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.
José António LopesDepartment of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.ORCID 0000-0001-5563-5132
Centro Hospitalar Lisboa Norte · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corona Virus Disease-19 (COVID-19) recently emerged as a global pandemic. Advanced age is the most important risk factor for increased virus susceptibility and worse outcomes. Many older adults are currently treated with renin-angiotensin-aldosterone system (RAAS) inhibitors and there is concern that these medications might increase the risk of mortality by COVID-19. This is a retrospective cohort of 346 patients older than 65 years with COVID-19, at the Department of Medicine of the Centro Hospitalar Universitário Lisboa Norte, in Portugal, hospitalized between March 2020 and August 2020. Mean age was 80.9 ± 8.7 years old. Most patients had arterial hypertension (n = 279, 80.6%), almost half (n = 161, 46.5%) had cardiovascular disease and approximately one-third of patients had heart failure (n = 127, 36.7%) or diabetes Mellitus (n = 113, 32.7%). Ninety-eight patients (28.3%) had chronic kidney disease and almost half of the patients (49.4%) were chronically under renin-angiotensin-aldosterone system (RAAS) inhibitors. Twenty percent of patients died during hospitalization. In a multivariate analysis, older age (OR 1.11, 95% CI 1.04, 1.18,

Indexed as

COVID-19elderlymortalityrenin–angiotensin–aldosterone system

Identifiers

PMID34300311
PMCPMC8307646
OpenAlexW3185156730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.